Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biomerica, Inc. (NASDAQ: BMRA).

Full DD Report for BMRA

You must become a subscriber to view this report.


Recent News from (NASDAQ: BMRA)

Biomerica Announces Fiscal Year End 2018 Financial Results
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185 versus net sales of $5,791,670 in fiscal 2017.    Net loss was $1,465,828 for fi...
Source: GlobeNewswire
Date: August, 30 2018 08:19
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity test...
Source: GlobeNewswire
Date: August, 02 2018 08:19
Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms Approximately 45 million Americans suffer from IBS 1 Studies being conducted at Beth Israel Deaconess Medical Center Inc., a Harvard Me...
Source: GlobeNewswire
Date: June, 25 2018 08:19
Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board
IRVINE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is chaired by Edward W. (Ned) Barnholt. Until recently, Dr. Leider served as Chief Medical Officer (CMO) and G...
Source: GlobeNewswire
Date: April, 19 2018 08:19
Biomerica reports Q3 results
Biomerica (NASDAQ: BMRA ): Q3 net loss of $0.32M More news on: Biomerica, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 17 2018 09:05
Biomerica Announces Third Quarter Financial Results
IRVINE, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,37...
Source: GlobeNewswire
Date: April, 17 2018 09:00
Mexico's COFEPRIS (Mexico's equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced the Mexico’s COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios - Mexico’s equivalent of the U.S. Food & Drug Administration) approval of the EZ Detect...
Source: GlobeNewswire
Date: March, 08 2018 08:19
Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: January, 26 2018 19:57
Biomerica reports Q2 results
Biomerica (NASDAQ: BMRA ): Q2 EPS of -$0.03 More news on: Biomerica, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: January, 16 2018 09:20
Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
IRVINE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,613,636 for the three months ended November 30, 2017, compared to $1,432,206 for the same period in the previous year, an increase of 12.7%.  Net sales were $3,058,119 for the...
Source: GlobeNewswire
Date: January, 16 2018 09:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-172.442.472.57922.448,772
2018-12-142.572.602.652.57654
2018-12-132.522.622.622.522,733
2018-12-122.54292.422.682.3919,280
2018-12-112.622.53982.622.5111,539

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-135001,20841.3907Short
2018-12-123,9049,21142.3841Short
2018-12-111,1392,16652.5854Short
2018-12-106802,28129.8115Cover
2018-12-071039,7100.0252Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BMRA.


About Biomerica, Inc. (NASDAQ: BMRA)

Logo for Biomerica, Inc. (NASDAQ: BMRA)

Biomerica, Inc. www.biomerica.com is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point of care in home and in physicians offices and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company s products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for diabetes, gastrointestinal disease and esoteric testing.

 

Contact Information

 

 

Current Management

  • Zackary S. Irani / CEO
  • Francis Capitanio / COO
  • Janet Moore / CFO, Secretary
  • Zackary S. Irani / Chairman
  • Allen Barbieri /
  • Dr. Francis Cano /
  • Jane Emerson /
  • Janet Moore /
  • Mark Sirgo /

Current Share Structure

  • Market Cap: $38,349,306 - 03/09/2018
  • Authorized: 25,000,000 - 10/10/2014
  • Issue and Outstanding: 8,541,048 - 01/11/2018
  • Float: 5,574,643 - 10/10/2014

 


Recent Filings from (NASDAQ: BMRA)

Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 10 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: January, 25 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: January, 25 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: January, 24 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: January, 24 2018

 

 


Daily Technical Chart for (NASDAQ: BMRA)

Daily Technical Chart for (NASDAQ: BMRA)


Stay tuned for daily updates and more on (NASDAQ: BMRA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BMRA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMRA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BMRA and does not buy, sell, or trade any shares of BMRA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/